Department of Anaesthesia, Pain Medicine & Critical Care, AIIMS, Ansari Nagar, New Delhi, India.
J Med Virol. 2021 Apr;93(4):2385-2395. doi: 10.1002/jmv.26740. Epub 2020 Dec 29.
The burden and impact of secondary superadded infections in critically ill coronavirus disease 2019 (COVID-19) patients is widely acknowledged. However, there is a dearth of information regarding the impact of COVID-19 in patients with tuberculosis, HIV, chronic hepatitis, and other concurrent infections. This review was conducted to evaluate the consequence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with concurrent co-infections based on the publications reported to date. An extensive comprehensive screening was conducted using electronic databases up to 3rd September 2020 after obtaining registration with PROSPERO (CRD420202064800). The observational studies or interventional studies in English, evaluating the impact of SARS-CoV-2 in patients with concurrent infections are included for the meta-analyses. Our search retrieved 20 studies, with a total of 205,702 patients. Patients with tuberculosis (RR = 2.10; 95% CI, 1.75-2.51; I = 0%), influenza (RR = 2.04; 95% CI, 0.15-28.25, I = 99%) have an increased risk of mortality during a co-infection with SARS-CoV-2. No significant impact is found in people living with HIV (RR = 0.99; 95% CI, 0.82-1.19; I = 30%), Chronic hepatitis (RR = 1.15; 95% CI, 0.73-1.81; I = 10%). Several countries (Brazil, Paraguay, Argentina, Peru, Colombia, and Singapore) are on the verge of a dengue co epidemic (cumulative 878,496 and 5,028,380 cases of dengue and COVID-19 respectively). The impact of COVID-19 in patients of concurrent infections with either tuberculosis or influenza is detrimental. The clinical outcomes of COVID-19 in HIV or chronic hepatitis patients are comparable to COVID-19 patients without these concurrent infections.
继发性合并感染在重症 2019 冠状病毒病（COVID-19）患者中负担和影响是广泛公认的。然而，关于合并结核病、HIV、慢性肝炎和其他合并感染的 COVID-19 患者的影响的信息却很少。本综述旨在评估基于迄今为止报告的出版物，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染对合并感染患者的后果。在获得 PROSPERO（CRD420202064800）注册后，我们使用电子数据库进行了广泛的综合筛选，截至 2020 年 9 月 3 日。纳入了评估 SARS-CoV-2 对合并感染患者影响的英语观察性研究或干预性研究进行荟萃分析。我们的检索共检索到 20 项研究，共纳入 205702 例患者。合并结核病（RR=2.10；95%CI，1.75-2.51；I=0%）和流感（RR=2.04；95%CI，0.15-28.25，I=99%）的患者在 SARS-CoV-2 合并感染期间的死亡率增加。在 HIV 感染者（RR=0.99；95%CI，0.82-1.19；I=30%）和慢性肝炎患者（RR=1.15；95%CI，0.73-1.81；I=10%）中未发现显著影响。几个国家（巴西、巴拉圭、阿根廷、秘鲁、哥伦比亚和新加坡）正处于登革热合并流行的边缘（登革热和 COVID-19 分别累积 878496 例和 5028380 例）。COVID-19 对合并结核病或流感感染患者的影响是有害的。HIV 或慢性肝炎患者的 COVID-19 临床结局与无这些合并感染的 COVID-19 患者相当。
